AbbVie (ABBV) Short-term Investments (2012 - 2025)

AbbVie has disclosed Short-term Investments across 14 years of filings, most recently posting $28.0 million for Q4 2025.

• In Q4 2025, Short-term Investments fell 9.68% year-over-year to $28.0 million; the TTM figure through Dec 2025 stood at $28.0 million (down 9.68% YoY), while the FY2025 annual figure was $28.0 million, down 9.68% from the prior year.
• Short-term Investments declined to $28.0 million in Q4 2025, from $42.0 million in the prior quarter.
• Over the last five years, Short-term Investments for ABBV reached as high as $1.5 billion in Q1 2022 and fell as low as $1.0 million in Q1 2025.
• The 5-year median for Short-term Investments is $28.0 million (2022), against an average of $178.8 million.
• Annual changes were most pronounced in 2022 — Short-term Investments soared 6600.0% — and 2023, when it slumped 99.51%.
• A 5-year view of Short-term Investments shows it stood at $84.0 million in 2021, then tumbled by 66.67% to $28.0 million in 2022, then slumped by 92.86% to $2.0 million in 2023, then surged by 1450.0% to $31.0 million in 2024, then fell by 9.68% to $28.0 million in 2025.
• According to Business Quant data, Short-term Investments over the past three periods registered $28.0 million, $42.0 million, and $1.0 million for Q4 2025, Q3 2025, and Q1 2025 respectively.